论文部分内容阅读
目的探讨采用厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗老年心力衰竭患者的临床效果。方法选取2014年1月至2015年1月沈阳市红十字会医院收治的老年心力衰竭患者88例为研究对象,均经临床检查确诊,按随机数字表法分为观察组和对照组,每组44例。观察组患者采用厄贝沙坦氢氯噻嗪联合美托洛尔治疗,对照组患者采用美托洛尔治疗,比较两组患者的治疗效果、治疗前后心功能指标变化及不良反应发生情况。结果治疗后,观察组及对照组患者临床治疗总有效率分别为95.5%、70.5%,差异有统计学意义(P<0.05);治疗前,两组患者心率、左心室射血分数、B型脑钠肽水平比较,差异均无统计学意义(均P>0.05);治疗后,两组患者心率、左心室射血分数、B型脑钠肽水平均明显改善,且观察组优于对照组,差异均有统计学意义(均P<0.05);观察组及对照组患者不良反应发生率分别为2.3%、18.2%,差异有统计学意义(P<0.05)。结论老年心力衰竭患者采用厄贝沙坦氢氯噻嗪早期联合美托洛尔治疗效果显著。
Objective To investigate the clinical efficacy of irbesartan and hydrochlorothiazide combined with metoprolol in the treatment of elderly patients with heart failure. Methods From January 2014 to January 2015, 88 cases of elderly patients with heart failure admitted to Shenyang Red Cross Hospital were enrolled in the study. All patients were diagnosed by clinical examination and divided into observation group and control group according to random number table. Each group 44 cases. The patients in the observation group were treated with irbesartan and hydrochlorothiazide combined with metoprolol. The patients in the control group were treated with metoprolol. The therapeutic effect was compared between the two groups. The changes of cardiac function indexes and adverse reactions before and after treatment were compared. Results After treatment, the total effective rate of clinical treatment in observation group and control group was 95.5% and 70.5%, respectively, with significant difference (P <0.05). Before treatment, heart rate, left ventricular ejection fraction, type B (P> 0.05). After treatment, heart rate, left ventricular ejection fraction and B-type natriuretic peptide in both groups were significantly improved, and the observation group was better than the control group (All P <0.05). The incidences of adverse reactions in the observation group and the control group were 2.3% and 18.2%, respectively, with significant differences (P <0.05). Conclusion Elderly patients with heart failure treated with irbesartan hydrochlorothiazide early metoprolol treatment effect is significant.